CAF-derived CXCL12 enhances the immune evasion of bladder cancer by inhibiting P62-mediated autophagic degradation of PD-L1, thereby promoting the growth of bladder cancer cells (51). This evidence concerns the gene CXCL12 and urinary bladder cancer.